The E-R relationship for safety in the proposed target patient population with early-stage ERBB 2-positive breast cancer is not characterized as PK data was not collected in the pivotal trial. Supportive E-R analyses for safety in patients with advance/metastatic breast cancer (n=345) suggested no apparent relationship between systemic neratinib exposure and the safety endpoints of any Grade diarrhea (≥ Grade 1), ≥ Grade 2 diarrhea, ≥ Grade 3 diarrhea, ≥ Grade 3 fatigue, elevated liver enzyme levels, and ≥Grade 1 rash (Figure 6).